Schedule

November 3, 2011
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD

Program Schedule

Thursday, November 3
8:00 am - 8:05 am	Welcome and Introductions Ignacio Melero, MD, PhD - University of Navarra
8:05 am - 8:35 am	The CITN Perspective on Immunotherapy Combinations Martin A. "Mac" Cheever, MD - Principal Investigator, Cancer Immunotherapy Trials Network (CITN);                                       Fred Hutchinson Cancer Research Center
8:35 am - 10:10 am	Session I: Immunotherapy Combinations with Other Immunotherapies Chair: Ignacio Melero, MD, PhD - University of Navarra
8:35 am - 8:40 am	Session Introduction Co-Chair: Ignacio Melero, MD, PhD - University of Navarra
8:40 am - 9:00 am	Differential Responses to Immunotherapy of Orthotopic Tumors Compared to Subcutaneous Tumors Michael H. Kershaw, PhD - Peter MacCallum Cancer Centre
9:00 am - 9:20 am	Optimising Agonistic Antibodies to Promote Anti-Cancer Responses Martin J. Glennie, PhD, University of Southampton
9:20 am - 9:40 am	PD-1 and CTLA-4 Combinations Gordon J. Freeman, PhD, Dana-Farber Cancer Institute
9:40 am - 10:10 am	Panel Discussion and Audience Q&A
10:10 am - 10:40 am	Break
10:40 am - 12:15 pm	Session II: Immunotherapy Combinations with Conventional Cancer Therapies Chair: Hideho Okada, MD, PhD - University of Pittsburgh Cancer Institute
10:40 am - 10:45 am	Session Introduction Co-Chair: Hideho Okada, MD, PhD, University of Pittsburgh Cancer Institute
10:45 am - 11:05 am	Unraveling Novel Pathways of Immunogenic Cell Death and Their Clinical Implications Laurence Zitvogel, MD, PhD, Institute Gustave Roussy
11:05 am - 11:25 am	Translational Development of Therapeutic Vaccines for Lymphoma Larry W. Kwak, MD, PhD, MD Anderson Cancer Center
11:25 am - 11:45 am	Cancer Vaccine Combinations with Conventional Therapies Philip M. Arlen, MD, National Cancer Institute, NIH
11:45 am - 12:15 pm	Panel Discussion and Audience Q&A
12:15 pm - 1:15 pm	Lunch Break
1:15 pm - 2:50 pm	Session III: Logistical Issues Chair:  Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine
1:15 pm - 1:20 pm	Session Introduction Co-Chair: Suzanne L. Topalian, MD, Johns Hopkins University School of Medicine
1:20 pm - 1:40 pm	Regulatory Perspectives on Combinatorial Immunotherapies Raj K. Puri, MD, PhD, U.S. Food and Drug Administration, CBER
1:40 pm - 2:00 pm	Developing Immunotherapy Combinations - Logistical Issues/Legal Matters David T. Bonk, JD, Bristol-Myers Squibb Company
2:00 pm - 2:20 pm	Combinatorial Approaches to Immune Therapy of Cancer: Building on Recent Success F. Stephen Hodi, Jr., MD, Dana-Farber Cancer Institute
2:20 pm - 2:50 pm	Panel Discussion and Audience Q&A
2:50 pm - 3:20 pm	Break
3:20 pm - 4:55 pm	Session IV: Clinical Trial Efforts: What Have We Learned? Chair:  Alan J. Korman, PhD - Bristol-Myers Squibb Company
3:20 pm - 3:25 pm	Session Introduction Co-Chair: Alan J. Korman, PhD, Bristol-Myers Squibb Company
3:25 pm - 3:45 pm	Combination Immunotherapy and BRAF Targeted Therapy for Melanoma Antoni Ribas, MD, UCLA Medical Center
3:45 pm - 4:05 pm	CD40 Immunotherapy for Cancer Robert H. Vonderheide, MD, DPhil, University of Pennsylvania
4:05 pm - 4:25 pm	Combination of Antibody Against CD137 with Other Anti Cancer Antibodies Ronald Levy, MD, Stanford University School of Medicine
4:25 pm - 4:55 pm	Panel Discussion and Audience Q&A
4:55 pm - 5:00 pm	Closing Comments Alan J. Korman, PhD - Bristol-Myers Squibb Company

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.